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SUMMARY
Nexplanon (Schering-Plough Limited/Merck Sharp &
Dohme Limited (MSD)) is a long active reversible
contraceptive method that provides effective
contraception for 3 years. It consists of a single, ﬂexible,
rod-shaped implant, containing 68 mg etonogestrel. It is
4 cm long, consists of an ethylene vinyl acetate
copolymer, a non-absorbable material, and also contains
15 mg of barium sulfate, which makes it visible by X-ray.
We describe a case of a 39-year-old woman who
experienced a local reaction to the barium sulfate in
Nexplanon. She was given medical treatment, but only
the removal of the implant resolved the symptoms. After
removal there was gradual improvement and 72 h later
the patient was asymptomatic. Allergic reaction to
barium sulfate is extremely rare: until now, there have
only been two cases associated with Nexplanon
described in the literature.
BACKGROUND
Nexplanon is a long active reversible contraceptive
method with progestogen and is effective for
3 years. It consists of a single, ﬂexible, rod-shaped
implant, containing 68 mg etonogestrel. It is 4 cm
long, consists of an ethylene vinyl acetate copoly-
mer, a nonabsorbable material and contains 15 mg
of barium sulfate.1 2 It was originally marketed
under the brand name Implanon (Schering-Plough
Limited/Merck Sharp & Dohme Limited (MSD)),
but was subsequently modiﬁed and marketed as
Nexplanon/Implanon NXT. The presence of sulfate
barium makes it visible on X-ray and is what differ-
entiates it from Implanon.2
Adverse reactions of etonogestrel implants that
lead to discontinuation include: abnormal uterine
bleeding, emotional instability, weight increase,
headache, acne and depression.
Implant site complications were reported by
3.6% of subjects during assessments in clinical
trials. Pain was the most frequent implant site com-
plication, reported during and/or after insertion,
occurring in 2.9% of subjects. Additionally, haema-
toma, redness and swelling were reported by 0.1%,
0.3% and 0.3% of patients, respectively.3
Allergic reaction to barium sulfate is extremely
rare. To date, only two cases associated with
Nexplanon have been reported in the literature.
CASE PRESENTATION
A 39-year-old Caucasian woman had a history of
etonogestrel non radiopaque (Implanon) implants
being placed on two occasions, without adverse
effect. She also had a history of allergic reaction to
multiple substances: lidocaine, iodine, copper,
lithium, mercury, uroﬂoxacin and bromocriptine.
As she was quite satisﬁed with Implanon, on
expiration of the second implant, she went to the
family physician for removal and reinsertion of a
new one. Nexplanon was placed in the non-
dominant arm.
About 48 h after insertion the patient reported
erythaema, oedema and local itching at the site of
insertion. She was not on any other medication at
the time. She was given ﬂucloxacillin 500 mg 8/8 h
and cetirizine hydrochloride 10 mg/day for 7 days.
She was re-evaluated 3 months later and due to
progressive worsening of the symptoms referred to
our institution. On observation, there was marked
oedema, with erythaema and itching lesions on the
inner side of the arm, without bruising or signs of
infection.
DIFFERENTIAL DIAGNOSIS
Initially, an implant site reaction was suspected, but
as the patient did not respond to the medications we
considered an allergic reaction to barium sulfate.
TREATMENT
The patient was started on therapy with topical
hydrocortisone (10 mg/g) for 5 days. After 1 week
she was revaluated and her symptoms remained the
same, so we decided to remove the Nexplanon
implant.
There was a gradual improvement in symptoms
and 3 days later the patient was asymptomatic.
OUTCOME AND FOLLOW-UP
The patient started taking continuous oral desoges-
trel 75 μg. At follow-up, 10 months later, she had
no signs of inﬂammatory/allergic reaction or scars
in the insertion site of the previous implant.
DISCUSSION
The occurrence of adverse reactions at the site of
insertion of implants includes: erythaema (3.3%),
haematoma (3%), bruising (2%), pain (1%) and swel-
ling (0, 7%). This is the third case reported in the lit-
erature of allergic reaction to the barium sulfate
present in Nexplanon.4 5 There are only two sub-
stances that did not exist in the previous etonogestrel
implants (Implanon): barium sulfate and magnesium
stearate. We know that our patient had taken other
medication with magnesium stearate without reac-
tion: gabapentin (neurontin), escitalopram (lexapro)
and desogestrel (cerazette). We therefore associated
the described allergic reaction of the new radiopaque
implant to barium sulfate.
We can consider this hypothesis and be alert to
the possibility of occurrence of this type of reaction
in women who had previously used Implanon and
who recently switched to Implanon.
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Unexpected outcome ( positive or negative) including adverse drug reactions
According to one study, allergic reactions to barium sulfate
are rare, occurring in about 2 per million.6 Barium sulfate in
suspension is frequently used clinically as a radiocontrast agent
for X-ray imaging and other diagnostic procedures. It is most
often used in imaging of the gastrointestinal tract and is admi-
nistered orally or by enema. Common side effects of barium
sulfate are: stomach cramps and incomplete or infrequent bowel
movements. Some rare side effects described are: constipation,
intense abdominal pain, life threatening allergic reaction, vomit-
ing, difﬁculty breathing or swallowing, diarrhoea, eczema, hives,
itching and redness of skin.7
The patient has been informed that she is probably allergic to
barium sulfate and was warned of possible future complications
from undergoing, for example, imaging examinations involving
contrast media. She was also referred to an immunoallergologist
consultation, where allergy tests to contrast agents were con-
ducted. The only contrast agent that she was not allergic to was
ioversol.
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Learning points
▸ It is important to bear in mind the possibility of allergic
reaction to any drug or substance in spite of the fact that it
may have been used safely in many patients over many years.
▸ It is also important to report any new adverse effect of a
drug to concerned authorities and in the literature.
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